Parenteral Manual

Scopolamine hydrobromide

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Anticholinergic agent
Original Date: 
August 2005
Revised Date: 
September 2011
  • Preoperative medication to produce amnesia and decrease salivation and respiratory secretions
  • DO NOT confuse with hyoscine butylbromide (Buscopan®)                   
Reconstitution and Stability: 
  • Available as 0.6 mg/mL ampoules
  • Store at room temperature                                       
  • Protect from light

- Solutions Compatible: SWI, D5W, NS, ringer's solution, ringer's lactate

- Additive/Above Cassette Compatible: atropine, chlorpromazine HCl, dimenhydrinate, diphenhydramine, droperidol, fentanyl, glycopyrrolate, hydromorphone, hydroxyzine, meperidine HCl, metoclopramide, morphine sulphate, pentobarbital sodium, prochlorperazine, promethazine HCl, thiopental; use within 15 minutes of mixing

- Y-site Compatible: heparin, propofol, KCl (up to 40 mmol/L)

- Incompatible: no information


(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

IV Direct

Usual dilution: dilute with an equal volume of Sterile Warter for Injection
Infusion time: over 2-3 minutes

IV Intermittent Infusion NO
IV Continuous Infusion NO

(For neonatal dosages, refer to Neonatal IV Drug Manual.)


  • 0.006 mg/kg/dose SC/IM/IV preop;  may repeat Q 6-8 hours if needed
  • Maximum dose: 0.3 mg/dose


  • 0.3-0.65 mg SC/IM/IV pre-operative; may repeat 3-4 times/day
Potential hazards of parenteral administration: 
  • Tachycardia, palpitations                                                             
  • Disorientation, delirium, confusion, hyperactivity - especially in children                                        
  • Urinary retention, constipation, dry mouth
  • Increased ocular pressure, dilation of pupils, blurred vision
  • Nausea, vomiting
  • Avoid use in patients with glaucoma, urinary or GI obstruction
  • Use with caution with hepatic or renal dysfunction, cardiac disease, seizures or psychoses
  • Antihistamines, phenothiazines and tricyclic antidepressants will enhance the drug's effects
  • Well absorbed orally;  injectable form may be given orally
  • Preoperative doses should be given 30-60 minutes prior to induction of anesthesia
  • DO NOT confuse with hyoscine butylbromide (Buscopan®)

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.